EMA Warning For Ariad’s Iclusig, While CHCs Get The Benefit Of The Doubt
This article was originally published in The Pink Sheet Daily
EMA doesn’t suspend, but warns on Ariad’s leukemia drug Iclusig for potential blood clots, while saying combined hormonal contraceptives’ benefit outweighs their risk.
You may also be interested in...
Company reluctantly agrees to FDA’s request to suspend sales of ponatinib due to serious thrombotic risks while a narrower label and Risk Evaluation and Mitigation Strategy are negotiated. FDA cites serious adverse vascular event rates of 48% and 24% in Phase I and II ponatinib trials, respectively.
The Pharmacovigilance Risk Assessment Committee is assessing whether use of third- and fourth-generation combined oral contraceptives should be limited to women who cannot take other birth control pills; this is the ninth group of drugs PRAC has been asked to review.
France has announced the suspension of Bayer’s acne drug, which is widely used as a contraceptive, after confirming its role in the death of four patients; a subsequent referral to the EMA could herald a Europe-wide suspension.